<DOC>
	<DOC>NCT03062618</DOC>
	<brief_summary>This study consists of three parts: single oral dose escalation in healthy volunteers (Part A), and multiple oral dose escalations in healthy volunteers (Part B) and in participants with chronic plaque psoriasis (Part C)</brief_summary>
	<brief_title>A Study of PRCL-02 in Healthy Volunteers and Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Parts A and B Be 18 to 55 years old Be healthy with absence of clinically significant illness Male participants must agree to use medically accepted methods of contraception with all sexual partners during the study, and for 90 days after Female participants must be postmenopausal or surgically sterile Have venous access sufficient for blood sampling Be a nonsmoker Part C Be 18 to 65 years old Have chronic plaque psoriasis based on a confirmed diagnosis of plaques for at least 6 months Have at least 4 evaluable plaques located in at least 2 body regions Parts A and B Significant abnormalities in vital signs, laboratory tests, electrocardiogram, or history of heart disease, some allergies, or infections Hepatic or renal impairment Hepatitis B, Hepatitis C, or Human Immunodeficiency Virus (HIV) Female participants who are pregnant or breast feeding Recent or ongoing infection History of alcohol or drug abuse Current or recent enrollment in a clinical trial judged not compatible with this study Part C Have highly active psoriatic arthritis Have pustular, erythrodermic and/or guttate forms of psoriasis Have had a clinicallysignificant flare of psoriasis during the last 12 weeks Currently or recently taking certain prescribed therapies for psoriasis Use of selected topical treatments within 4 weeks prior to starting the study (use of some emollients without urea is allowed, except on one lesion for biopsy)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>